Hormonal birth control is one of the most effective non-surgical treatments for adenomyosis, and it’s typically the first option doctors recommend. The hormonal IUD (sold as Mirena or Liletta) is generally considered the primary therapy because of its strong track record for reducing both pain and heavy bleeding. Combined oral contraceptives and progestin-only pills also help, though they work differently and may be better suited depending on your specific symptoms.
How Hormonal Birth Control Works Against Adenomyosis
Adenomyosis is driven by estrogen. Tissue similar to the uterine lining grows into the muscular wall of the uterus, where estrogen fuels its growth and causes the muscle to thicken and contract abnormally. This leads to heavy periods, severe cramping, and a progressively enlarged uterus.
Hormonal birth control attacks this process from multiple angles. The progestin component causes the endometrial tissue, both where it belongs and where it’s invaded the muscle wall, to thin out and become inactive. This reduces its sensitivity to estrogen, slows estrogen production within the tissue itself, and lowers the levels of inflammatory compounds (prostaglandins) that drive pain. The result is less bleeding, less cramping, and in some cases a measurable reduction in the thickness of the affected uterine wall.
Combined oral contraceptives add a second mechanism: by suppressing ovulation, they keep overall estrogen levels more stable and lower than in a natural cycle. Studies have found that women with adenomyosis who took oral contraceptives had a significantly thinner affected zone in the uterine wall compared to untreated women.
The Hormonal IUD: First-Line Treatment
The levonorgestrel-releasing IUD consistently outperforms other hormonal options for adenomyosis symptom control. It releases progestin directly into the uterus, creating a high local concentration right where the disease is active. This causes the ectopic tissue to shrink while avoiding many of the systemic side effects that come with oral medications.
The numbers are striking. Within 12 months of IUD placement, average menstrual blood loss drops by about 75%. Pain scores in clinical studies fell from roughly 94 out of 100 to about 58, a reduction of nearly 40%. Uterine volume also decreases significantly within the first three months.
There is one important limitation: the IUD doesn’t work for everyone with adenomyosis. Women whose uterus has become significantly enlarged (deeper than 8 cm on ultrasound) or whose shape has been distorted by the disease may not be good candidates. In some cases, extremely heavy menstrual flow can actually expel the device. If the IUD isn’t an option for anatomical reasons, other hormonal approaches can fill the gap.
Oral Contraceptives and Progestin-Only Pills
Combined oral contraceptives (the standard birth control pill) work for adenomyosis primarily by inducing thinning and inactivity of the endometrial tissue. They’re particularly useful for managing heavy bleeding and are often prescribed in a continuous regimen, skipping the placebo week, to eliminate monthly withdrawal bleeds entirely. Treatment guidelines suggest targeting oral contraceptives toward patients whose primary complaint is heavy bleeding.
Dienogest, a progestin-only pill available in many countries, has gained attention specifically for adenomyosis treatment. It halts the growth of ectopic endometrial cells by freezing them in a resting state and blocking estrogen-driven proliferation. Clinical evidence shows it provides faster and stronger pain relief than the hormonal IUD in the first three months of use, though the IUD catches up and may surpass it for bleeding control by 12 months. Over three years of continuous use, dienogest produces significant sustained improvement in period pain, pain during sex, and heavy menstrual bleeding.
Side effects of dienogest include irregular vaginal bleeding (especially in the first few months), missed periods, hot flashes, and mood changes. These are generally mild to moderate.
The Contraceptive Implant as an Alternative
The subcutaneous progestin implant (Nexplanon) offers another route for women who can’t use the IUD. A small study of 17 patients found that the implant provided meaningful symptom relief for women with adenomyosis, including those whose uterine cavity was too large or distorted for IUD placement, and those who had previously expelled an IUD due to heavy flow. It works through the same progestin-driven mechanism, delivered through the bloodstream rather than locally in the uterus. While the evidence base is smaller than for the IUD, it’s a practical option when other approaches aren’t feasible.
What Birth Control Won’t Do
Hormonal birth control manages symptoms effectively, but it doesn’t cure adenomyosis. The disease tissue remains in the uterine wall. When you stop treatment, symptoms typically return.
There’s also a nuance around uterine size that matters. While the hormonal IUD can shrink the uterus in the early months, oral contraceptives and progestin-only pills are less reliable on this front. A study comparing treatments over 16 weeks found that oral contraceptives reduced uterine volume in only about 47% of patients, and dienogest in about 55%. Some patients in both groups actually saw their uterus double in size during treatment. By contrast, injectable GnRH medications (a stronger hormonal therapy with more significant side effects) shrank the uterus in 96% of patients. If uterine enlargement is your primary concern, the pill alone may not be enough.
For women whose symptoms don’t respond adequately to hormonal birth control, hysterectomy remains the only definitive treatment. Hormonal options are best understood as long-term management tools, effective for many women, but not a permanent solution.
How Quickly Symptoms Improve
Most women notice changes within the first three months of starting hormonal treatment, though the timeline varies by method. Dienogest tends to provide the fastest pain relief, with significant improvement in cramping within those initial months. The hormonal IUD takes slightly longer to reach full effect for pain but shows measurable reductions in bleeding and uterine size by three months. Bleeding patterns with any hormonal method can be unpredictable in the first few months before settling into a more manageable pattern.
Long-term use appears to maintain and even deepen the benefits. Studies tracking patients on progestin therapy for three or more years show continued symptom improvement over time, suggesting these treatments don’t lose effectiveness with prolonged use. For most women with adenomyosis, hormonal birth control is not a short-term fix but an ongoing management strategy that works best when sustained.